CORRECTED-Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin
February 13, 2019 at 13:34 PM EST
British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of $210 million, including some future payments.
